Alectinib halts lung cancer growth more than a year longer than crizotinib
Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ...
Jun 5, 2017
0
1